Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-label Extension Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100

NCT01534052 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT01534052
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01534052 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-label Extension Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Completed
Start date
October 21, 2011
Completion date
April 18, 2017
Enrollment
52 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate cancer (crpc)